Strides Pharma Science is currently trading at Rs. 611.40, up by 27.35 points or 4.68% from its previous closing of Rs. 584.05 on the BSE.
The scrip opened at Rs. 636.65 and has touched a high and low of Rs. 636.65 and Rs. 596.60 respectively. So far 13397 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1675.25 on 17-Oct-2024 and a 52 week low of Rs. 530.70 on 27-Jan-2025.
Last one week high and low of the scrip stood at Rs. 715.00 and Rs. 551.00 respectively. The current market cap of the company is Rs. 5634.83 crore.
The promoters holding in the company stood at 26.82%, while Institutions and Non-Institutions held 45.41% and 27.77% respectively.
Strides Pharma Science's a wholly owned subsidiary -- Arco Lab has incorporated a new wholly owned subsidiary namely ‘Pivot Path’ on April 10, 2025. Pivot Path shall focus on life sciences and manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities.
Industry to which the entity being incorporated belongs to outsourcing and business support services for all processes, sub-processes, transactions, activities and all other work performed in various industries with specific emphasis on pharmaceutical sector, within India and across the world.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: